Summary of Clinical Use

Phase 3 clinical trials for lung cancer have been completed. See for example NCT00006352.

Mechanism Of Action and Pharmacodynamic Effects

GD3 ganglioside is widely expressed in human malignant melanoma cell lines and tumours [2] and antibodies against ganglioside have been shown to induce tumour cell death [3]. It is believed that gangliosides like GD3 are involved in the tumour cell attachment critical to invasion and metastasis. Vaccination with a GD3 mimic is designed to enhance immunogenicity against GD3 [4].